EU Obesity Treatment Market Analysis

$2,350.00$4,700.00

  • Type: Common Disease Area
  • Published : March 2021
  • Region: Europe
  • Country: NA
  • Report ID : 689

  • Format: PPT, PDF

EU Obesity Treatment Market: Size, Share, Segmentation by Type (Inactivity Obesity, Food Obesity, Anxiety Obesity, Venous Obesity, Atherogenic Obesity, and Gluten Obesity), by Diagnosis (Blood Tests, Physical Examination, and Others) and by Treatment (Medication, Surgery, Lifestyle Changes)- Industry Analysis and Forecast (2019-2028)

Clear
SKU: 689 Categories: ,

Report Overview

The EU Obesity Treatment Market was valued at USD 1.96 Billion in 2019 and is projected to reach USD XX Billion by 2028, growing at a CAGR of XX% during the forecast period

Obesity is a complex disorder involving an excessive amount of body fat and thus increasing the risk of diseases and health diseases, high blood pressure, and diabetes. Obesity is diagnosed when the body mass index (BMI) is 30 or higher. It is caused by a number of factors such as an unhealthy diet, inactive lifestyle, consumption of alcohol, and lack of sleep. According to country estimates, more than 50% of both men and women in the EU were overweight, and roughly 23% of women and 20% of men were obese. In the EU, 1 in 3 eleven-year-olds were obese. Certain medications such as antidepressants, steroids, and beta-blockers as well as genes, as well as pregnancy can lead to obesity

Market Growth Drivers

The growing obese population, increasing number of bariatric surgeries, increasing incidence of lifestyle diseases, rising disposable income, and growing fast food industry are expected to drive the market growth. The EU obesity treatment market is propelled by a number of factors such as various government initiatives regarding overweight issues, technological advancements in the medical sector, commercial easy availability of weight management treatments. Many companies are engaged in the launch of new devices and medications with minimum side effects

1. EU Obesity Treatment Market Overview………..………………..………………………….….
A. Market Size
2. Market Growth Drivers………………………………………………………………………..……………..
A. Growing obese population, and number of bariatric surgeries in the EU
B. Increasing incidence of lifestyle diseases and growing fast food industry
C. Government initiatives, and technological advancements in the Medical sector
3. EU Obesity Treatment Market Segmentation……………………………………………………….
A. By Nutrient Type
I. Inactivity Obesity
II. Food Obesity
III. Anxiety Obesity
IV. Venous Obesity
V. Atherogenic Obesity
VI. Gluten Obesity
B. By Diagnosis
I. Blood Tests
II. Physical Examination
III. Others
C. By Treatment
I. Medication
II. Surgery
III. Lifestyle Changes
IV. Others
4. EU Obesity Treatment Market Share…………………………………………..………………..…..
A. Market Analysis, Insights and Forecast to 2028 by Revenue
5. Competitive Landscape……………………………………………..…………………………….………..
A. Major Players
B. Products in Pipeline
6. Key Company Profiles………………………………………..…………………………………..………….
A. Orexigen Therapeutics Ltd. company overview, Product & Services, Strategies & Financials
B. Roche pharmaceuticals overview, Product & Services, Strategies & Financials
C. Novo Nordisk company profile, Product & Services, Strategies & Financials
7. Healthcare Policies and Regulatory Landscape………………………………………….…
A. Policy changes and Reimbursement scenario
8. Potential Growth Opportunities……………………………………..……………………..…………
A. Advancements in drug development
9. Factors Driving Future Growth…………………………………………….…………………………..
A. Key Industry Trends and Recent Developments in EU Obesity Treatment Market
B. Future Opportunities
10. Conclusion

 

Market Segmentation

The EU Obesity Treatment market is segmented on the basis of Type, Diagnosis, and Treatment

By Type:

On the basis of type, the market is segmented into Inactivity Obesity, Food Obesity, Anxiety Obesity, Venous Obesity, Atherogenic Obesity, and Gluten Obesity

By Diagnosis:

On the basis of Diagnosis, the market is categorized into Blood tests, Physical Examination, and Others. The blood test segment is sub-segmented into cholesterol tests, liver function tests, thyroid tests, and others. The physical examination segment is sub-segmented into heart rate measurement, blood pressure measurement, and others

By Treatment:

On the basis of treatment, the market is segmented into Medication, Surgery, Lifestyle Changes, and Others. The medication segment is sub-segmented into orlistat, lorcaserin, phentermine and topiramate, liraglutide, and others. The surgery segment is sub-segmented into gastric bypass surgery, Laparoscopic Adjustable Gastric Banding (LAGB), gastric sleeve, biliopancreatic diversion, gastric sleeve, and others

Key Players

The major drugs that are available in the EU market for the treatment of Obesity are Liraglutide, Orlistat, and a combination of bupropion/naltrexone. The key players in the EU market are Roche Pharmaceuticals, Novo Nordisk, Orexigen Therapeutics Ltd. Liraglutide is an antidiabetic drug manufactured by Novo Nordisk Mysimba works on the parts of the brain that regulate appetite, reducing food cravings and suppressing feelings of hunger. Mysimba developed by Orexigen Therapeutics Ltd, showed promising results in clinical trials and was recently launched across the EU

 

Methodolgy description

Download Free Sample Report






    This report addresses

    • Market intelligence to enable effective decision making
    • Growth opportunities and trens analysis
    • Eget est lorem ipsom dolor sit. sem nulla pharetra diam sit amet
    • Eget est lorem ipsom dolor sit. sem nulla pharetra diam sit amet
    • Eget est lorem ipsom dolor sit. sem nulla pharetra diam sit amet
    • Eget est lorem ipsom dolor sit. sem nulla pharetra diam sit amet

    Need more?

    • Speak to our analyst to know how this research was put together
    • Add more countries or regions as part of customisation
    • Understand how this report can have direct impact on your revenue

    Get a custom report based on your requirements